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It has been >40 yr since the observation that 
lymphoblasts isolated from intestinal LNs pref-
erentially home to the intestine when com-
pared  with  their  counterparts  derived  from 
skin-draining peripheral LNs (pLNs; Griscelli 
et al., 1969; Hall et al., 1977). It has subsequently 
been shown that such gut-specific migration is 
a result of T and B cells activated within the 
gut-associated-lymphoid tissue (GALT) selec-
tively up-regulating the expression of homing 
receptors, such as 47 and CCR9, whose li-
gands (MadCAM and CCL25, respectively) are 
largely restricted to the intestinal tract (Campbell 
and Butcher, 2002; Johansson-Lindbom et al., 
2003). In addition to inducing the expression 
of gut-specific homing receptors, intestinal LNs 
(i.e., mesenteric LN [mLN] and Peyer’s patch) 
have been reported to support the development 
of peripherally generated FoxP3+ regulatory 
T cells (Annacker et al., 2005; Coombes et al., 
2007)  and  isotype  class  switching  to  Ig-A 
(Shikina et al., 2004; Mora et al., 2006). Con-
sequently, the concept that the GALT is special-
ized in driving immune responses tailored to 
the intestinal mucosa has emerged.
It is generally accepted that the DCs that lo-
calize to the GALT are the architects of this gut-
tropism. Reductionist studies have demonstrated 
that DCs taken from the intestinal LNs, but not 
splenic  or  skin-draining  pLNs,  induce  47 
and CCR9 expression upon T and B cell prim-
ing (Johansson-Lindbom et al., 2003; Mora et al., 
2003, 2006) and also promote FoxP3 expres-
sion in a TGF-–dependent manner (Annacker 
et al., 2005; Coombes et al., 2007; Mucida et al., 
2007). This activity has been further restricted 
to a subset of CD103-expressing DCs that orig-
inate from the lamina propria and migrate to 
the draining LNs in a CCR7-dependent man-
ner (Annacker et al., 2005; Johansson-Lindbom 
et  al.,  2005;  Coombes  et  al.,  2007).  CD103+ 
DCs appear to be the major DC subset involved 
in trafficking antigen from intestine to LN and 
are potent activators of T cells within the LN 
(Jaensson et al., 2008; Schulz et al., 2009).
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The production of retinoic acid (RA) by dendritic cells (DCs) is critical for the induction of 
gut-tropic immune responses by driving the expression of intestinal-specific homing recep-
tors, such as 47 and CCR9, upon T and B cell activation. However, how RA production is 
regulated during DC development remains unclear. We describe an unexpected role for 
prostaglandin E2 (PGE2) as a negative regulator of retinal dehydrogenases (RALDH), the 
enzymes responsible for RA synthesis. The presence of PGE2 during DC differentiation inhib-
ited RALDH expression in mouse and human DCs, abrogating their ability to induce CCR9 
expression upon T cell priming. Furthermore, blocking PGE2 signaling increased the fre-
quency of RALDH+ DCs in vitro, and reducing PGE2 synthesis in vivo promoted the systemic 
emergence of RA-producing DCs and the priming of CCR9+ T cells in nonintestinal sites such 
as the spleen. Finally, we found that PGE2 stimulated the expression of the inducible cyclic 
AMP early repressor, which appears to directly inhibit RALDH expression in DCs, thus provid-
ing mechanistic insight into how PGE2 signaling down-modulates RALDH. Given the role of 
PGE2 in regulating the development of RA-producing DCs, modulating this pathway may 
prove a novel means to control the development of gut-tropic immune responses.
© 2011 Stock et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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as the intestine does not switch on RALDH expression ubiq-
uitously. Indeed, not all intestinal DCs express the RALDH 
enzyme during the steady state (Jaensson et al., 2008; Schulz 
et al., 2009), whereas monocyte-derived DCs (mo-DCs) in-
filtrating the intestine during periods of inflammation do not 
acquire RALDH activity (Siddiqui et al., 2010). Furthermore, 
dermal-derived CD103+CD11b DCs are also dependent on 
GM-CSF for development (King et al., 2010) but do not ex-
press the RALDH enzyme in vivo (Guilliams et al., 2010).
To address the mechanisms regulating the development of 
RA-producing DCs in vivo, we sought to identify potential 
factors that regulate RALDH expression during DC differen-
tiation. In this paper, we describe an unexpected role for 
prostaglandin E2 (PGE2) as a negative regulator of RALDH 
expression in both mice and human DCs. Consequently, modu-
lating PGE2 signaling during DC development dramatically 
altered the ability of DCs to prime gut-homing T cells. Given 
the central role for RA-producing DCs in promoting gut-
tropic immunity, our findings suggest that modulating PGE 
signaling may be a powerful approach by which to control the 
tissue specificity of developing immune responses.
RESULTS
Multiple factors can induce RALDH expression in a wide 
range of DCs in vitro
To investigate the development of RA-producing DCs, we 
initially screened a panel of factors for their ability to induce 
the expression of the RALDH enzymes that convert retinal 
to RA. To measure RALDH activity, we used the commer-
cially available substrate aldefluor (ALD), which is converted 
into a fluorescent product by RALDH enzymes, allowing the 
identification of RALDH-expressing cells by flow cytometry. 
Consistent with previous studies (Yokota et al., 2009; Guilliams 
et al., 2010), we found that although the spleen was devoid of 
ALD fluorescent cells, a subset of CD11c+ cells in both the 
mLNs (23%) and skin-draining pLNs (9%) converted the 
ALD substrate and fluoresced, indicating functional RALDH 
enzymes (Fig. 1 a). To confirm that ALD fluorescence corre-
lated with RALDH activity and RA production, we sorted 
mesenteric CD11c+ DCs into ALD-positive and -negative 
subsets (Fig. 1 b) and found that only the ALD+ DCs ex-
pressed the RALDH2 transcript (Fig. 1 c). Second, although 
both subsets stimulated robust peptide-specific T cell prolifer-
ation in vitro (Fig. S1 a), the ability to drive CCR9 expression 
upon T cell priming was enriched and restricted to ALD+ 
DCs (Fig. 1 d). Thus, ALD fluorescence appears to mark the 
subset of DCs that express RALDH2 and have a unique abil-
ity to prime CCR9 expression, which is consistent with the 
synthesis of RA (for convenience herein we shall refer to the 
ALD+/ cells as RALDH+ and RALDH). Consistent with a 
previous study (Guilliams et al., 2010), the RALDH+ CD11c+ 
cells from the mLN were positive for CD103 and heteroge-
nous for CD11b, whereas the RALDH+ DCs isolated from 
the skin-draining pLNs were CD103CD11b+, suggesting 
that RALDH activity was common to differing DC subsets 
in vivo (Fig. S1 b).
The mechanisms by which intestinal DCs drive the ex-
pression of gut-homing receptors was first described by Iwata 
et al. (2004), with the seminal observation that retinoic acid 
(RA) triggered the expression of the gut-tropic homing re-
ceptors during T cell priming. Subsequent studies have shown 
that RA similarly drives 47/CCR9 expression on B and   
T cells in mice and humans (Jaensson et al., 2008) and is at 
least partly involved in the generation of FOX-P3+ regulatory 
T cells and Ig-A switching (Coombes et al., 2007; Mucida   
et al., 2007). RA is the active metabolite of vitamin A, being 
synthesized via a multi-step pathway whereby retinol is 
converted into the intermediate retinal by the ubiquitously 
expressed alcohol dehydrogenase enzymes, and then into RA 
by a family of retinal dehydrogenase enzymes (RALDH) that 
are  expressed  in  a  more  restricted  manner  (Napoli,  1999; 
Duester, 2000). Critically, the RALDH enzymes that control 
RA synthesis are highly expressed by CD11c+ DCs from in-
testinal LNs but are absent from splenic DCs, correlating with 
the former being able to produce RA (Iwata et al., 2004).   
A more detailed analysis has demonstrated that RALDH ex-
pression is restricted to the CD103+ subset of mLN DCs 
(Coombes et al., 2007). Collectively, these findings suggest 
that CD103+ intestinal DCs, by virtue of RALDH expres-
sion, are uniquely endowed with the capacity to produce RA, 
which in turn drives the expression of genes appropriate for in-
testinal immunity. Recently however, a population of RALDH-
expressing CD103CD11b+ DCs that originate in the dermis 
and  lung  has  also  been  previously  described  (Guilliams   
et al., 2010). These DCs were capable of priming FoxP3+ reg-
ulatory T cells in vitro, suggesting that a similar mechanism is 
in place for the generation of regulatory T cells against lung- 
and skin-derived self-antigens.
What controls the expression of the RALDH enzymes, 
and thus the ability to synthesize RA, remains unclear. One 
possibility is that RALDH expression is restricted to lineage-
specific  DCs. Alternatively,  RALDH  expression  may  be 
regulated by the local microenvironment. Because RALDH-
expressing intestinal CD103+ DCs and RALDH-negative 
conventional lymphoid CD8 DCs appear to be develop-
mentally related—both are derived from common DC pre-
cursors and are dependant upon the transcription factors Irf8 
and Batf3 for development (Bogunovic et al., 2009; Varol   
et al., 2009; Edelson et al., 2010)—it is unlikely that RALDH 
expression is restricted to DCs of a unique lineage. Instead, 
the observations that feeding mice a vitamin A–deficient diet 
dramatically reduces DC RALDH expression in vivo (Yokota 
et al., 2009) and that multiple factors, including GM-CSF,   
IL-4, IL-13, and the TLR-2 ligand zymosan, can induce in 
vitro RALDH expression (Manicassamy et al., 2009; Yokota   
et al., 2009) suggest that the gut microenvironment may be 
capable of inducing RALDH expression through the provi-
sion of soluble factors. Indeed, it has been reported that intes-
tinal CD103+ DC development is dependent on GM-CSF 
(Bogunovic et al., 2009), a potent inducer of RALDH ex-
pression in vitro. However, how the expression of the RALDH 
enzymes by DCs is regulated in vivo remains to be clarified, JEM VOL. 208, April 11, 2011 
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which appears to be enhanced by LPS. Together, 
this data shows that multiple factors can induce 
RALDH expression in vitro and that DCs that 
do not express RALDH in vivo have the poten-
tial to do so in response to these positive signals.
Stromal cell–derived factors inhibit RALDH 
expression during DC differentiation
Given that RALDH activity is restricted to a   
minor subset of DCs in vivo, it was surprising that 
such a large proportion of DCs could be induced to express 
RALDH  in  vitro  by  a  wide  panel  of  factors  including   
GM-CSF. We therefore postulated that RALDH expres-
sion may be actively suppressed in vivo by negative regulators. 
The stroma is emerging as major source of molecules that mod-
ulate DC activity, and we wondered whether stromal-derived 
factors might also be involved in regulating DC RALDH ex-
pression. To this end, we differentiated DCs from BM precur-
sors with GM-CSF in the presence of supernatants (SNs) 
derived from a panel of stromal or lymphocyte cell lines. 
Again, culturing BM with GM-CSF alone drives the differ-
entiation of RALDH-expressing DCs, which account for 
25% of CD11c+ cells (Fig. 2 a). However, when BM- 
derived DCs (BM-DCs) were differentiated with GM-CSF 
in the presence of SN taken from a primary skin stromal line 
or the 3T3 fibroblast line, RALDH+ DCs failed to develop 
(Fig. 2 a). This suppressive activity was restricted to SN puri-
fied from stromal cell lines, as SN from the thymoma EL-4 
To examine what factors can induce RALDH expression 
during DC development, we differentiated DCs from BM 
precursors with FLT3-L in the presence of a panel of immune 
factors. Although FLT3-L can drive the differentiation of 
CD11c+ DCs from BM precursors, FLT3-L alone does not 
induce RALDH expression (Fig. 1 e). Consistent with an ear-
lier study (Yokota et al., 2009), the addition of anyone of 
GM-CSF, RA, IL-4, IL-13, and, to a lesser degree, thymic 
stromal lymphopoietin (TSLP) resulted in the emergence of 
RALDH+ DCs, suggesting that each of these factors can in-
duce the expression of RALDH during DC development 
(Fig. 1 e). To examine whether GM-CSF would also induce 
RALDH activity in differentiated lymphoid DCs, we sorted 
RALDH CD11c+ cells from the mLN, skin draining pLN, 
and spleen and cultured them with GM-CSF for 48 h before 
measuring RALDH activity. As seen in Fig. 1 f, a large frac-
tion of sorted RALDH DCs from all organs up-regulated 
the RALDH enzyme in response to GM-CSF, an activity 
Figure 1.  Identification of factors that induce RALDH 
expression in vitro. (a) mLN, skin-draining pLN, or spleens 
from C57BL/6 mice were digested, treated with ALD, and 
stained with anti-CD11c antibodies for analysis by flow 
cytometry. A representative dot plot of ALD and CD11c ex-
pression from at least seven experiments is shown with 
inset values indicating the percentage of live (PI) CD11c+ 
DCs that are ALD+. The mean was taken from between 11 
and 23 mice. (b–d) CD11c+ mLN cells sorted into ALD+ and 
ALD subsets. (c) The expression of RALDH2 mRNA by ALD+ 
and ALD DC subsets was examined by RT-PCR (values 
indicate molecular mass of PCR product). (d) NP366–374 pep-
tide–pulsed total CD11c+ mLN DCs or CD11c+ DCs sorted 
into ALD+ or ALD subsets were used to stimulate CFSE-
labeled CD8+ F5 T cells in vitro. After 4 d, the expression of 
CCR9 on dividing T cells was analyzed by flow cytometry. 
The graph shows the mean percentage of dividing T cells 
that express CCR9 with SEM pooled from two independent 
experiments. (e) BM cells were cultured with FLT3-L in the 
presence of the indicated factors. After 3 d, LPS was added 
and, 18 h later, cells were treated with ALD and stained with 
CD11c. Shown is the percentage of CD11c+ DCs that are ALD 
positive. The mean was taken from two experiments with 
SEM. (f) ALD CD11c+ DCs isolated from the mLN (mes), 
pLN, or spleen were cultured with GM-CSF and/or LPS for 
48 h before analysis of RALDH activity by ALD staining.  
A representative contour plot of ALD and CD11c expression 
is shown. Inset values show the mean percentage of CD11c 
cells that are ALD+ pooled from three experiments.764 PGE2 inhibition of retinoic acid–producing DCs | Stock et al.
expression. Indeed, although skin SN–conditioned DCs had 
lost the ability to induce CCR9 expression, they had an   
enhanced ability to drive P-selectin ligand (PSL) expression, a 
lectin involved in tethering to nonintestinal endothelial (Fig. 2 d).   
These phenotypic differences correlated with distinct hom-
ing potential in vivo. When transferred into congenic recipi-
ents at equivalent frequencies, although both  T cell populations 
were found at equal numbers in the spleen, T cells primed by 
control DCs homed more effectively to the small intestine 
epithelial, whereas T cells primed by skin SN–conditioned 
DCs had an enhanced capacity to traffic into inflamed skin 
(Fig. 2 e). In summary, this data shows that the stroma can 
produce  soluble  factors  that  suppress  RALDH  expression 
during DC differentiation, limiting the development DCs   
capable of priming gut-homing T cells.
PGE2 inhibits RALDH expression during DC differentiation
We next sought to identify the soluble factor produced by 
skin stroma that inhibits DC RALDH expression. The ability 
did not impair the development of RALDH-expressing DCs 
at any concentration (Fig. 2, a and b). Consistent with the loss 
of RALDH+ activity, CD11c+ DCs differentiated in the pres-
ence of skin SN expressed substantially less RALDH2 mRNA, 
suggesting that RALDH inhibition occurs at a transcriptional 
level (Fig. 2 c). Importantly, although CD11c+ DCs cultured 
with skin SN do not develop RALDH expression, the ex-
pression of MHC class II and CD86 by CD11c+ DCs was 
equivalent to that of control DCs (Fig. S2 a). Furthermore, 
skin SN–conditioned DCs produced equivalent or enhanced 
levels of IL-12 upon TLR stimulation, suggesting that the loss 
of RALDH activity was not a consequence of general dys-
function (Fig. S2 b). Consistent with this, when pulsed with 
the influenza NP366–374 peptide, both control and skin SN–
conditioned DCs could drive the proliferation of the CD8+ 
NP366–374–specific F5 T cells in vitro, as measured by the se-
quential loss of CFSE fluorescence (Fig. 2 d). However, only 
control BM-DCs induced CCR9 expression on dividing   
T  cells,  which  is  consistent  with  their  intact  RALDH   
Figure 2.  Stromal-derived factors inhibit DC RALDH 
expression. (a and b) BM from C57BL/6 mice was cultured 
with GM-CSF alone or in the presence of SNs derived from 
primary mouse skin lines (skin), 3T3 fibroblasts, or EL-4 cells. 
After 3 d, LPS was added and, 18 h later, cells were stained 
with ALD and CD11c to measure DC RALDH activity. (a) A 
representative contour plot depicting the expression of CD11c 
and ALD is shown with inset values indicating the percentage 
of CD11c+ DCs that are ALD+. (b) BM was differentiated, as in 
a, with SNs at various concentrations. Bar graphs show the 
mean percentages of CD11c+ DCs that are ALD+ with SD. Data 
were pooled from between 2 and 18 experiments. (c) DCs 
were differentiated from BM with GM-CSF alone or in the 
presence of skin SN. Cells were treated with LPS at day 3.  
16–18 h later, DCs were purified with anti-CD11c or MHC class 
II microbeads and analyzed for RALDH2 expression by real-time 
qPCR. RALDH2 expression was normalized to GAPDH. Shown 
is relative expression of RALDH2 by skin SN versus control 
DCs, with each dot representing an individual experiment and 
horizontal bars the pooled mean. (d) DCs were differentiated 
from BM with GM-CSF alone, or in the presence of skin SN. 
After 3 d, LPS was added and, 18 h later, MHC class II+ DCs 
were purified, pulsed with NP366–374-peptide, and used to 
stimulate CFSE-labeled CD8+ F5 T cells. 4 d later, the expres-
sion of CCR9 and PSL was analyzed by flow cytometry. Dot 
plots show the expression of homing receptors versus CFSE 
on live (PI) TCR+ cells. Inset values are the mean percentage 
of dividing T cells positive for each receptor pooled from be-
tween 7 and 17 experiments. (e) CD8+ F5 T cells were acti-
vated as in d. After 4 d, T cells were labeled with CFSE or CTO, 
pooled at a 1:1 ratio, and transferred into congenic B6.Ly5.1 
recipients (2 × 106/recipient) that had been primed with 
oxazolone and challenged on the ear. After 16–18 h, the rela-
tive frequency of donor (CD45.2+) T cells primed by control 
versus skin SN-conditioned DCs at the various sites was de-
termined by flow cytometry. A representative contour plot 
gated on live (PI) CD45.2+ donor T cells is shown, where 
control T cells are labeled with CTO and skin SN DC-primed  
T cells with CFSE. Inset is the mean frequency of each popula-
tion pooled from three independent experiments.JEM VOL. 208, April 11, 2011 
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the skin SN (at 2 ng/ml or 5–10 nM), but not in SN, from 
indomethacin-treated skin stroma (Fig. 3 d). Intriguingly, ex-
ogenous PGE2 alone, in the absence of skin SN, had a re-
duced suppressive activity (Fig. S3), suggesting that the skin 
SN enhances the delivery or responsiveness to PGE2. None-
theless, this data suggests that stromal-derived PGE2 inhibits 
the differentiation of RALDH-expressing DCs.
Deficiency in PGE2 receptor subtype 4 (EP-4) enhances  
DC RALDH expression
To further examine whether PGE2 signaling negatively regu-
lated the expression of the RALDH enzymes, we asked whether 
mice  deficient  in  PGE2  receptors  had  aberrant  RALDH   
activity. PGE2 signals through four receptors: EP-1, -2, -3, or -4. 
These are G-protein–coupled receptors that have distinct 
downstream signaling events (Sugimoto et al., 2000; Sugimoto 
and Narumiya, 2007). We used genetically engineered mice 
that lack each individual EP receptor to examine whether a 
PGE2 receptor deficiency enhanced RALDH expression 
(Segi et al., 1998; Ushikubi et al., 1998; Hizaki et al., 1999).   
To this end, we differentiated DCs with GM-CSF from BM 
isolated from either WT or EP-KO mice in the presence or 
absence of skin SN before measuring RALDH activity. As 
seen in Fig. 4, compared with their WT 129 controls, BM 
to suppress RALDH expression was maintained in skin SN 
that had been heated or digested with trypsin, indicating 
that the active factor was unlikely to be a protein or a peptide 
(Fig. 3 a). We next tested whether a lipid may be responsible 
for RALDH inhibition. To this end, we grew skin stroma lines 
in the presence of lipid inhibitors to block the production of 
ceramides (fumonisin B1; He et al., 2006), prostaglandins 
(indomethacin;  Nakata  et  al.,  1981),  or  glycosphingolipids 
(N-butyldeoxynojirimycin [NBDJ]; Andersson et al., 2000),   
thus generating skin SN depleted of these various lipid species. 
As seen in Fig. 3 a, although skin SN depleted of ceramides or 
sphingolipid retained maximal suppressive activity, SN from 
indomethacin-treated skin stroma had a substantially reduced 
ability to suppress the development of RALDH-expressing DCs. 
Indomethacin inhibits the cyclooxygenase (COX) enzymes, 
which convert arachidonic acid to prostaglandin H, which is 
then converted into one of five active metabolites: PGD2, 
PGE2, PGF, PGI, or thromboxane (Katler and Weissmann, 
1977; Fig. 3 b). We asked whether these prostaglandins could 
rescue the suppressive activity of indomethacin-treated skin 
SN. As seen in Fig. 3 c, the addition of exogenous PGE2, but 
not of the other prostaglandins, restored the suppressive abil-
ity of indomethacin-treated skin stroma SN. Consistent with 
PGE2 as the active factor, endogenous PGE2 was detected in 
Figure 3.  Stroma-derived PGE2 inhibits RALDH expression during DC differentiation. (a) BM-DCs were differentiated with GM-CSF in the presence 
of skin stroma SN that had been heated at 80°C or digested with trypsin, or SN derived from skin stroma grown in the presence of fumonisin B1 (FB1), 
indomethacin (indo), or NBDJ. After 3 d, LPS was added and, 18 h later, cells were stained with ALD and CD11c to analyze DC RALDH activity. Bar graphs 
show the mean relative inhibition of ALD+ CD11c+ DCs between treated SN and untreated parent SN with SD. Relative inhibition was calculated as described 
in Materials and methods. Values were pooled from 2–10 experiments. (b) Pathway of prostaglandin synthesis. (c) BM cells were cultured with GM-CSF 
alone or in the presence of SN from WT or indomethacin-treated skin stroma (SN at 25% culture volume). 0.1 µM of exogenous individual prostaglandins 
subtypes was added at the beginning of culture. After 3 d, LPS was added and, 18 h later, cells were stained with ALD and CD11c to analyze DC RALDH  
activity. A representative contour plot of CD11c versus ALD staining is shown with inset values of the mean percentage of CD11c+ DCs that are ALD+ pooled 
from three experiments. (d) The concentration of PGE2 in skin stromal SN was determined by ELISA. Shown is the mean with SD from seven individual lines.766 PGE2 inhibition of retinoic acid–producing DCs | Stock et al.
RALDH-expressing DCs in the spleen that would in turn 
drive CCR9 expression during T cell activation. To this end, 
we transferred CFSE-labeled CD8+ F5 T cells into C57BL/6 
recipients and, 1 d later, elicited priming within the spleen 
through the i.v. injection of the NP366–374 peptide with LPS in 
combination with indomethacin treatment. 60 h later, we ana-
lyzed RALDH activity by splenic CD11c+ DCs and the ex-
pression of CCR9 on dividing F5 T cells. As seen in Fig. 5, 
indomethacin  administration  reduces  splenic  PGE2  levels 
(Fig. 5 a) and results in a four to fivefold increase in RALDH-
expressing splenic DCs (Fig. 5 b). Critically, in comparison 
with untreated mice where dividing F5 T cells do not express 
CCR9, a large fraction (43%) of dividing T cells up-regulate 
CCR9  in  indomethacin-treated  mice,  which  is  consistent 
with the enhanced RALDH expression by local splenic DCs 
(Fig. 5 c). Thus, inhibiting prostaglandin synthesis allows the 
emergence of RALDH-expressing DCs in nonintestinal sites 
such as the spleen, which in turn prime gut-homing T cells at 
this site.
PGE2 inhibits RALDH expression in human mo-DCs
We next wished to examine whether PGE2 similarly regu-
lated RALDH expression in human DCs. To this end, we 
cultured CD14+ monocytes with GM-CSF and IL-4 in the 
presence or absence of prostaglandins and asked: (a) does 
GM-CSF/IL-4 induce RALDH expression in human mo-DCs; 
and (b) does PGE2 inhibit this induction? As seen in Fig. 6, 
although monocytes do not express RALDH2 mRNA,   
differentiation with GM-CSF and IL-4–induced RALDH   
expression by mo-DCs as measured by both ALD staining 
and RT-PCR (Fig. 6, a and b). Consistent with our previous 
experiments, PGE2, but none of the other prostaglandins, in-
hibited RALDH expression at a protein and mRNA level, 
suggesting that PGE2 suppressed RALDH transcription in 
human mo-DCs (Fig. 6, a and b). We next asked which PGE2 
receptor was signaling RALDH inhibition in human mo-DCs. 
from  EP-4–deficient  mice  gave  rise  to  a  significantly  en-
hanced  frequency  of  RALDH+  DCs  when  cultured  with 
GM-CSF alone (Fig. 4, a and b). Second, although the skin 
SN  completely  abolished  the  development  of  RALDH+ 
DCs from WT or EP-1, -2, or -3 KO BM, a population of 
RALDH+ DCs did emerge from EP-4 KO BM cultured with 
skin SN (Fig. 4, a and b). EP-4 deficiency did not alter other 
aspects of BM-DC development, in terms of DC frequency 
or phenotype, with equivalent levels of CD86, CD11b, or 
CD103 expression by EP-4 KO and WT BM-DCs (Fig. S4 a). 
Thus, the absence of EP-4 signaling appeared to enhance DC 
RALDH expression selectively. Consistent with PGE2 signaling 
via EP-4 to inhibit RALDH expression, the EP-4–specific 
agonist ONO-AE1-329 (Sugimoto and Narumiya, 2007; Jones 
et al., 2009), but not EP-1, -2, or -3 agonists, inhibited DC 
RALDH expression similar to PGE2 (Fig. 4 c). However, it is 
important to note that in vivo, EP-4 KO mice only showed a 
statistically significant increase in the frequency of RALDH+ 
DCs in the pLNs but not the mLN or spleen (Fig. S4). Given 
this modest phenotype in vivo, it is probable that some redun-
dancy between other PGE2 receptors, notably EP-2, which, 
like EP-4, enhances cAMP (Sugimoto et al., 2000), or alter-
nate factors may exist in vivo.
Limiting PGE2 levels in vivo promotes the emergence  
of RALDH-expressing DCs in the spleen and the priming  
of gut-homing T cells systemically
Given our findings in vitro, we wished to examine whether 
reducing PGE2 synthesis would increase the frequency of 
RA-producing DCs in vivo. Splenic DCs do not express 
RALDH and consequently fail to induce the expression of the 
gut-homing receptor CCR9 during T cell priming (Johansson- 
Lindbom et al., 2003; Iwata et al., 2004). Given that PGE2 is 
present within the spleen in the steady state (Fig. 5 a), we 
asked whether limiting PGE2 systemically—through the i.v. 
injection of indomethacin—would result in the emergence of 
Figure 4.  EP-4 deficiency enhances BM-DC RALDH expression. (a and b) BM cells from EP-KO or WT C57BL/6 and 129 mice were cultured with 
GM-CSF alone or in the presence of skin SN. After 3 d, LPS was added and, 18 h later, cells were stained with CD11c and ALD to measure DC RALDH activity. 
(a) Bar graph shows the mean percentage of CD11c+ DCs that are ALD+ for each mouse genotype with SEM pooled from four experiments (***, P < 0.001). 
(b) A representative contour plot of CD11c and ALD expression of EP-4 KO and WT 129 BM-DCs is shown. Inset values indicate the MFI of ALD  
expression by CD11c+ DCs. (c) BM cells were cultured with GM-CSF in the presence of exogenous PGE2 or EP-specific agonists (cultures comprised 25% 
SN from indomethacin-treated skin stroma to enhance PGE2 responsiveness). Indomethacin was added at the beginning of culture to block endogenous 
PGE2 synthesis. After 3 d, LPS was added and, 18 h later, cells were stained with CD11c and ALD to measure DC RALDH activity. Graph shows the mean ± 
SEM of the percentage of CD11c+ DCs that are ALD+ pooled from three experiments.JEM VOL. 208, April 11, 2011 
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(AE1-259) was substantially more potent, completely inhibit-
ing RALDH expression with an activity equivalent to PGE2 
(Fig. 6 d). Thus, similar to what we observe in mice, PGE2   
inhibits  RALDH  transcription  during  DC  differentiation. 
However, in contrast to mouse BM-DCs, this activity appears 
to be mediated predominantly through PGE2–EP-2 signal-
ing. Given this distinction, we compared the PGE2 receptor 
expression by mouse BM-DCs and human mo-DCs sorted 
into RALDH+ and RALDH subsets (Fig. 6, e and f). Con-
sistent with their sensitivity to EP-2 signaling, human mono-
cytes  and  both  RALDH-negative  and  -positive  mo-DCs 
express EP-2 in addition to EP-4 (Fig. 6 e). However, in the 
case of mouse BM-DCs, although both DC subsets expressed 
EP-4, EP-2 expression was restricted to RALDH-negative 
DCs (Fig. 6 f). Therefore, although human mo-DCs express 
both EP-2 and EP-4 and are highly sensitive to EP-2-PGE2 
signaling, mouse RALDH+ BM-DCs have diminished EP-2 
receptor expression and are consequently refractory to EP-2–
specific agonists.
PGE2 elicits inducible cAMP early repressor (ICER), which 
inhibits RALDH expression and is expressed by RALDH  
but not RALDH+ DCs in vivo
Our findings demonstrate that PGE2 inhibits RALDH tran-
scription signaling via either EP-2 (in human mo-DCs) or 
EP-4 (for mouse BM-DCs). Both EP-2 and EP-4 are Gs 
protein–coupled receptors that increase intracellular cAMP 
(Sugimoto et al., 2000). This suggests that the suppression of 
RALDH expression is likely to be downstream of an increase 
in intracellular cAMP. Consistent with this, the addition of 
the dibutyryl cAMP analogue (dB-cAMP) during mo-DC dif-
ferentiation similarly suppressed the development of RALDH+ 
DCs in vitro (Fig. S5). How would increased cAMP inhibit 
RALDH expression? Elevated cAMP regulates gene expres-
sion via the phosphorylation of downstream nuclear transcrip-
tion factors of the cAMP response element (CRE) binding 
protein (CREB)/CRE modulator (CREM)/activating tran-
scription factor 1 (ATF-1) family (Borrelli et al., 1992; Mayr 
and Montminy, 2001). These proteins bind at conserved CRE 
binding sites (TGACGTCA), initiating the transcription 
of CRE-responsive genes (Borrelli et al., 1992; Mayr and 
Montminy, 2001). However, cAMP can also give rise to proteins 
that repress the transcription of CRE-responsive genes. No-
tably, cAMP can drive the expression of the ICER, a trun-
cated CREM protein that lacks a trans-activation domain and 
thereby represses the transcription of genes whose promoters 
contain CRE-binding sites (Foulkes et al., 1991; Foulkes and 
Sassone-Corsi, 1992; Molina et al., 1993). Given that RALDH2 
transcription is repressed by PGE2, and that the RALDH2 
promoter contains multiple CRE-binding sites (Wang et al., 
2001),  we  speculated  that  PGE2  might  repress  RALDH2 
transcription  through  the  induction  of  ICER.  Consistent 
with this possibility, PGE2 induced ICER mRNA and pro-
tein expression in both CD11c+ mouse BM-DCs and human 
mo-DCs in vitro (Fig. 7, a–d). To test whether ICER regulates 
RALDH expression, we differentiated DCs with GM-CSF 
Using a panel of EP-specific antagonists, we found that 
AH6809, an antagonist for EP-1 and EP-2 (Jones et al., 2009), 
enhanced the frequency of RALDH-positive DCs in the ab-
sence of exogenous PGE2, suggesting that some level of 
endogenous PGE2 was limiting RALDH expression in culture 
(Fig. 6 c). Second, AH6809 blocked the complete suppression 
of RALDH+ DCs after the addition of exogenous PGE2. 
Given that the EP-1–specific antagonist SC1990 (Jones et al., 
2009) had no effect, AH6809 is presumably acting by block-
ing EP-2 signaling. Surprisingly, the EP-4 antagonist AH23848 
also had no effect on RALDH expression. We extended this 
analysis by using EP-specific agonists to ask which agonists 
could recapitulate PGE2 activity. It is of note that these ex-
periments were performed in the presence of indomethacin 
to limit endogenous PGE2 production. As seen in Fig. 6 d, 
agonists for EP-1 or EP-3 showed negligible activity, whereas 
EP-4–specific agonists (AE1-329) partially limited the devel-
opment of RALDH+ DCs (Sugimoto and Narumiya, 2007). 
Consistent with the antagonist data, the EP-2–specific agonist 
Figure 5.  Indomethacin administration promotes the emergence of 
splenic RALDH+ DCs in vivo and the priming of CCR9+ T cells sys-
temically. (a–c) 5 × 105 CFSE-labeled CD8+ F5 T cells were transferred 
into C57BL/6 mice and, 1 d later, mice received 50 µg NP366–374-peptide 
plus 10 µg LPS via i.v. tail vein injection (NPp+LPS). Indomethacin-treated 
mice received 100 µg indomethacin i.v. 1 h before peptide and then once 
daily. 60 h after NP366–374 peptide injection, mice were sacrificed and the 
spleens analyzed. (a) The concentration of PGE2 was determined in spleen 
homogenate by ELISA. Shown is the mean with SEM from three to five 
mice pooled from two experiments. (b) Splenocytes were treated with ALD 
and stained with CD11c and CD3 (to gate out to CFSE+ T cells). Shown is 
the mean percentage of CD3-CD11c+ DCs that are ALD+ in the spleen. 
Mean with SEM from 7–11 mice per group is shown, pooled from four 
experiments. (c) Splenocytes were stained with antibodies against CD8 
and CCR9. Dot plots were gated on live (PI) CD8+ CFSE+ T cells and show 
the expression of CCR9 and CFSE on donor F5 T cells. Inset value is the 
mean percentage of dividing T cells that are CCR9+ pooled from between 
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from BM of either WT or CREM/ICER-deficient mice and 
compared their RALDH activity. Consistent with ICER in-
hibiting RALDH transcription, CREM/ICER KO BM-DCs 
had significantly higher levels of RALDH activity compared 
with their WT counterparts (Fig. 7 e). Given that ICER in-
hibits DC RALDH expression in vitro, we next asked whether 
the subset of DCs that express RALDH in vivo do so in part 
by an ability to avoid ICER expression. To this end, we mea-
sured ICER expression directly ex vivo comparing RALDH+ 
and RALDH DC subsets sorted from mLNs and skin-draining 
pLNs (Fig. 7 f). Intriguingly, we found a reciprocal expression 
between ICER and RALDH2, with little or no ICER mRNA 
being detected in RALDH+ DCs, whereas ICER was ex-
pressed by RALDH DCs isolated from both mLN and skin-
draining pLNs (Fig. 7 f). Furthermore, ICER expression 
coincided with EP-2, with both being expressed exclusively 
by RALDH DCs. This is consistent with our observation for 
BM-DCs, again indicating that RALDH+ DCs do not ex-
press EP-2. These patterns of expression are consistent with 
the possibility that those DCs that express the RALDH en-
zymes in vivo do so, in part, by limiting ICER expression, 
possibly by virtue of reduced PGE–EP-2 signaling.
DISCUSSION
The production of RA by DCs is critical for driving the de-
velopment of gut-tropic immune responses (Iwata et al., 2004; 
Coombes et al., 2007; Jaensson et al., 2008). However, the fac-
tors that regulate RA synthesis by DCs remain poorly de-
fined. Consistent with others (Yokota et al., 2009), we show 
that in reductionist in vitro settings, multiple factors, most 
notably GM-CSF, can induce RALDH expression in both 
mouse and human DCs. Indeed GM-CSF was able to induce 
RALDH activity even by RALDH-negative lymphoid DCs 
stimulated ex vivo. Despite this observation that multiple 
factors—many of which are widely available in vivo—can elicit 
RALDH expression in vitro, the capacity to produce RA is 
highly restricted to defined subsets of DCs in vivo. We there-
fore speculated that in vivo, negative regulators of RALDH 
might act to limit the systemic emergence of RA-producing 
DCs. Consistent with this possibility we discovered that PGE2 
blocked RALDH expression induced by GM-CSF, repressing 
the transcription of the RALDH enzymes in both mouse and 
human DCs. Consistent with an inhibitory role, blocking 
PGE2 signaling via receptor antagonists or using BM precur-
sors that were deficient in the PGE2 receptor subtype 4 (EP-4) 
gave rise to an enhanced frequency of RALDH+ DCs in vitro, 
whereas reducing PGE2 levels in vivo resulted in the emer-
gence of RA-producing DCs in the spleen that were capable of 
priming CCR9+ gut-homing T cells at this site. These findings 
Figure 6.  PGE2 inhibits RALDH expression in human mo-DCs.  
(a and b) DCs were differentiated from CD14+ monocytes purified from 
buffy coats with GM-CSF and IL-4 alone or in the presence of 0.1 µM of 
exogenous prostaglandin subtypes. Indomethacin was included to stop 
endogenous prostaglandin synthesis. After 3 d, LPS was added and, 18 h 
later, cells were harvested and analyzed for RALDH expression by RT-PCR 
and ALD staining. (a) RALDH2 expression analyzed by RT-PCR. Duplicate 
samples were derived from two independent experiments using different 
donors. (b) A representative contour plot of ALD and CD86 expression is 
shown with the mean percentage of ALD+ of CD86+ DCs inset. Values were 
pooled from two independent experiments with different donors. (c) CD14+ 
monocytes were differentiated with GM-CSF/IL-4 alone or with 25 µM PGE2 
in the presence of antagonists against EP-1/2 (AH6809), EP-1 (SC19220), or 
EP-4 (AH23848). After 3 d, LPS was added and, 18 h later, cells were treated 
with ALD and stained with CD86 to measure DC RALDH activity. Bar graphs 
show mean percentage of CD86+ DCs that are ALD+ with SEM. Data were 
pooled from three independent experiments. (d) CD14+ monocytes were 
differentiated with GM-CSF/IL-4 with indomethacin in the presence of PGE2 
or EP-specific agonists at varying concentrations. After 3 d, LPS was added 
and, 18 h later, cells were treated with ALD and stained with CD86 to mea-
sure DC RALDH activity. Line graph shows the mean percentage of CD86+ 
DCs that are ALD+ with SEM, pooled from three independent experiments.  
(e and f) Human mo-DCs or mouse BM-DCs generated as described were 
treated with ALD and stained with CD86 or CD11c, respectively, and sorted 
into CD86+ RALDH+/ or CD11c+ RALDH+ and RALDH subsets. The expres-
sion of EP-2 and EP-4 was examined by RT-PCR. Duplicates were from dif-
ferent cDNA obtained from two independent experiments and donors 
(values indicate molecular mass of PCR product).
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that BM-DCs from mice lacking ICER had significantly 
enhanced  RALDH  activity  suggest  that  ICER  actively 
limits RALDH expression during DC development. Given 
that PGE2 stimulates ICER expression in mouse and human 
DCs, we propose that PGE2 most likely represses the tran-
scription of RALDH via the induction of ICER. Second, our 
finding that ICER was absent or expressed at substantially 
reduced levels by RALDH+ DCs in vivo suggests that RA-
producing DCs express the RALDH enzyme, in part as a re-
sult of their unique ability to limit or avoid ICER expression. 
Collectively, these results provide a mechanistic insight into 
how PGE2 signaling would drive the transcriptional repres-
sion of RALDH.
Why those RA-producing DCs that emerge in vivo do 
not express ICER and how they escape PGE-mediated RALDH 
inhibition remains an outstanding question. One possibility is 
that these DCs may develop in microenvironments devoid of 
PGE2. However, PGE2 is present constitutively in the small 
intestine at levels similar to that found in the skin and spleen 
(Fig. S6). Furthermore, it is well established that DCs, includ-
ing those found in the mLNs, produce PGE2 (Broere et al., 
2009). For these reasons, we feel it likely that RALDH+ DCs 
are exposed to PGE2 in vivo. Alternatively, PGE2 signaling 
may fail to induce ICER expression in this DC subset, thus 
leaving  the  transcription  of  RALDH  unhindered. A  third 
possibility is that RALDH+ DCs are themselves refractory to 
PGE2. Although this issue warrants further studies, it is in-
triguing that mouse RALDH+ DCs that emerge both in vitro 
and in vivo do not express the EP-2 receptor, whereas their 
RALDH-negative counterparts do. Although EP-4 signaling 
are consistent with an earlier observation in madine-darby 
canine kidney cells (Napoli, 1993) and suggest that PGE2 is a 
negative regulator of RALDH expression in DCs that effec-
tively limits the emergence of RA-producing DCs.
PGE2 appears to inhibit RALDH expression at the tran-
scriptional level. Of the four PGE2 receptors (EP-1–4), PGE2 
signaled  predominantly  through  EP-2  to  inhibit  RALDH 
transcription in human mo-DCs and EP-4 in mouse BM-
DCs. Both EP-2 and EP-4 are Gs protein–coupled receptors 
whose engagement results in adenyl cyclase release and an in-
crease in intracellular cAMP (Sugimoto et al., 2000). Given 
this, in addition to the fact that the cAMP analogue similarly 
suppressed RALDH, it is likely that the inhibition of RALDH 
expression is downstream of cAMP. Elevated cAMP leads to 
the phosphorylation of nuclear transcription factors of the 
CREB/CREM/ATF-1 family (Mayr and Montminy, 2001). 
When phosphorylated, these can recruit cofactors that in 
complex bind at conserved CRE binding sites (TGACGTCA) 
and thereby initiate the transcription of CRE-responsive 
genes (Borrelli et al., 1992; Mayr and Montminy, 2001). How-
ever, CREB/CREM/ATF-1 will also drive the expression of 
the ICER that is transcribed from the intronic CRE-P2 pro-
moter of CREM. ICER is a truncated protein that lacks the 
trans-activation  domain  of  CREM  but  retains  the  DNA-
binding motif and thereby acts as a repressor of CRE-responsive 
genes (Foulkes et al., 1991; Foulkes and Sassone-Corsi, 1992; 
Molina et al., 1993). Given that the RALDH2 promoter 
contains multiple CRE binding sites (Wang et al., 2001), the 
induction  of  ICER  proteins  has  the  potential  to  repress 
RALDH2 transcription. Consistent with this, our findings 
Figure 7.  PGE2 induces ICER expression, 
which limits RALDH activity in vitro and  
is selectively expressed by RALDH- DCs  
in vivo. (a–d) Mouse CD11c+ BM-DCs or human 
mo-DCs were treated with 1 µM PGE2 and 
analyzed for ICER expression by RT-PCR and 
Western blot analysis at the indicated times 
after treatment. A representative from at least 
two independent experiments is shown.  
(a) RT-PCR for ICER expression by mouse  
BM-DCs. Isoforms I & II run as a 208-bp prod-
uct and isoforms I/II as a 169-bp product.  
(b) RT-PCR for ICER expression in human  
mo-DCs. Isoforms I & II run as 657- and 257-bp 
product, respectively. (c and d) Western blot 
for ICER protein expression by mouse BM-DCs 
(c) and human mo-DCs (d). Values indicate 
the position of protein ladder markers (kD).  
(e) BM cells from CREM/ICER null mutant mice 
or WT controls were cultured with GM-CSF.  
After 3 d, LPS was added and, 18 to 24 h later, 
cells were stained with CD11c and ALD to 
measure DC RALDH activity. A representative contour plot of CD11c and ALD expression of CREM/ICER KO and WT (WT) BM-DCs is shown. Inset values 
indicate the mean percentage of CD11c+ DCs that are ALD+. Bar graph shows the ALD MFI of CD11c+ DCs with SEM. Data were pooled from two experi-
ments (*, P < 0.05). (f) CD11c+ cells were purified from the mLN or pLN of C57BL/6 mice, treated with ALD, and sorted into CD11c+RALDH+ and RALDH 
subsets by flow cytometric sorting. The expression of RALDH2, ICER, and PGE2 receptors was analyzed by RT-PCR. Duplicates are with cDNA derived from 
different mice, and a representative of at least four independent experiments is shown (values indicate MW of PCR product).770 PGE2 inhibition of retinoic acid–producing DCs | Stock et al.
Given that PGE2 is commonly used in clinical trials to 
mature mo-DCs used for immunotherapy (Jonuleit et al., 1997; 
Schadendorf et al., 2006), our findings have immediate impli-
cations within this setting. PGE2 treatment would reduce 
RALDH activity and thereby enhance the capacity of DCs to 
activate T cells capable of migrating to nonintestinal sites, 
such as the skin, and thus would be highly appropriate when 
eliciting T cells response to cancers such melanoma. In con-
trast, blocking PGE2 signaling would enhance RALDH   
expression and, thus, the ability of DCs to prime CCR9+ 
gut-homing T cells that would be most effective against intes-
tinal cancers. Second, our findings that indomethacin treat-
ment promoted the systemic priming of CCR9+ T cells raises 
the possibility that the administration of COX inhibitors in 
combination with vaccines may be a means to elicit gut-tropic 
immune responses after parenteral inoculations. Given that most 
vaccines are delivered via subcutaneous or intramuscular injec-
tions, routes which do not typically elicit gut-homing T cells, 
this approach maybe beneficial when vaccinating against patho-
gens, such as HIV, that replicate within the intestinal tract. 
Thus, we suggest that manipulating DCs’ exposure to PGE2 
may be a means to enhance the efficacy of T cell immunity 
via controlling the tissue specificity of such responses.
In summary, we show in this paper that although multiple 
factors can elicit the expression of RALDH during DC dif-
ferentiation, PGE2 provides a dominant inhibitory signal that 
represses the transcription of RALDH. The development of 
RA-producing DCs may therefore reflect a balance between 
the ability to respond to positive stimuli, such as GM-CSF 
which drives RALDH expression, while ignoring or subvert-
ing the inhibitory stimuli such as PGE2 that elicit transcrip-
tional repression. Given the central role that RA-producing 
DCs play in the induction of gut-specific immunity, we be-
lieve that modulating PGE2 signaling during DC differentia-
tion may therefore be a powerful means to manipulate the 
tissue tropism of immune responses.
MATERIALS AND METHODS
Mice. C57BL/6, F5, and B6.SJL-PtprcaPep3b/BoyJ (B6Ly5.1) mice were 
maintained at the Biological Services Unit at John Radcliffe Hospital (Uni-
versity of Oxford). F5 TCR transgenic mice express a TCR specific for the 
H2-Db-restricted A/NT/60/68 influenza nucleoprotein peptide NP68366–374-
ASNENMDAM (Mamalaki et al., 1993). Mice with deletions in one of   
Ptger1 (EP-1), Ptger2 (EP-2), Ptger3 (EP-3), or Ptger4 (EP-4) were generated   
as previously described (Segi et al., 1998; Ushikubi et al., 1998; Hizaki et al., 
1999). With the exception of EP-4/, these mice were backcrossed at least 
eight times onto the C57BL/6 background. Ptger4/ mice do not survive 
on the C57BL/6 background as a result of patent ductus arteriosus (Segi et al., 
1998) and were backcrossed on a mixed background of 129/Ola × C57BL/6. 
Mice were provided by S. Narumiya (Kyoto University, Kyoto, Japan), and breed-
ing colonies were maintained by M. Belvisi at Imperial College London 
(London, England, UK). CREM/ICER-deficient mice were generated as previ-
ously described (Blendy et al., 1996; Conti et al., 2004). Mutant and WTs are 
F1 hybrids (129SVEV:C57BL/6) obtained by crossing heterozygous CREM/
ICER +/ 129SVEV N12 × CREM/ICER+/ C57BL/6 N15. Mice were 
provided by J. Blendy (University of Pennsylvania School of Medicine, Philadel-
phia, PA) and colonies were maintained at the Department of Pharmacology 
(University of Pennsylvania School of Medicine). All mice were used under   
institutional guidelines with the authority of a UK Home Office project license.
does drive RALDH inhibition in mouse BM-DCs, in the 
case of human monocytes (which express both EP-2 and -4), 
PGE2–EP-2 signaling was clearly the dominant pathway for 
RALDH inhibition. Blocking signaling through EP-2, but 
not  EP-4,  abrogated  PGE2-mediated  RALDH  inhibition, 
whereas EP-2 agonists were substantially more potent in 
comparison with their EP-4 counterparts on human mo-DCs. 
The enhanced activity of EP-2 may relate to PGE2–EP-2 signal-
ing, providing a more sustained signal compared with EP-4, as 
the latter is internalized after stimulation, whereas EP-2 does   
not undergo agonist induced desensitization (Nishigaki et al., 
1996; Desai et al., 2000). Given that EP-2 is the dominant recep-
tor  for  signaling  RALDH  inhibition  in  human  mo-DCs, 
coupled with the finding that RALDH+ DCs are devoid of 
EP-2, it is tempting to speculate that RALDH-expressing 
DCs arise from a unique precursor that does not express EP-2 
and are thus refractory to PGE2. Although this is possible, it is 
important to note that mice lacking the EP-2 receptor did 
not show an increase in RALDH+ DCs in vivo. Thus, the ab-
sence of EP-2 does not alone explain the development of 
RALDH+ DCs, potentially as the result of a level of redun-
dancy between EP-2 and -4 or additional inhibitory factors 
that  also  drive  the  phosphorylation  of  CREB  proteins.   
Consequently, the exact mechanism that enables RA-producing 
DCs to escape PGE2-mediated RALDH inhibition remains 
unclear and is an area of ongoing research.
Early inflammatory molecules, such as IL-1 and TNF, in-
duce the expression of COX-2 and thereby increase local 
PGE2 production (Alaaeddine et al., 1999; Dinarello, 2002). 
As such, DCs differentiating at the site of inflammation, in-
cluding inflammatory monocytes which infiltrate inflamed 
tissues, are likely to be exposed to high concentrations of 
PGE2. With this in mind, it is interesting that inflammatory 
mo-DCs infiltrating the GALT during periods of colitis do 
not acquire RALDH activity (Siddiqui et al., 2010). Instead, 
these inflammatory mo-DCs produce high levels of IL-23, a 
cytokine which is enhanced by PGE2 (Khayrullina et al., 
2008), and appear to augment Th-17 responses that in turn 
exacerbate intestinal pathology (Siddiqui et al., 2010). Our 
findings, which establish a link between PGE2 and RALDH 
expression, may help to explain why inflammatory mo-DCs 
fail to acquire the capacity to produce RA. Given that RA-
producing DCs potently inhibit Th-17 differentiation and in-
stead favor the differentiation of FOXP-3 regulatory T cells 
(Mucida et al., 2007), defining the processes which underpin 
the loss of RA-producing DCs during periods of chronic in-
flammation may have important implications in understand-
ing the onset immunopathology.
Our results clearly demonstrate that PGE2 treatment modu-
lates how DCs program homing receptor expression during   
T cell priming. Reducing PGE2 levels in vivo enhanced the 
ability of DCs to drive CCR9 expression upon T cell activa-
tion, whereas DCs differentiated in the presence of exogenous 
PGE2 lost the capacity to induce CCR9, instead showing 
an enhanced ability to elicit the expression of nonintestinal 
homing  receptors,  such  as  PSL,  upon  activated T  cells. JEM VOL. 208, April 11, 2011 
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microbeads (Miltenyi Biotec) and cultured in 6-well plates (106 cells/well) in 
RP-10 with 50 ng/ml of human recombinant GM-CSF (PeproTech) and 
IL-4 (5%). After 3 d, 1 ng/ml LPS was added and cells were harvested the 
next day. In some instances, 1 µM indomethacin was added at the beginning 
of culture to block the endogenous prostaglandin.
PCR. RNA was extracted with RNA easy kit (QIAGEN) as per manufac-
turer’s instructions. cDNA was synthesized from 20 ng RNA with oligo-dT 
primers (Invitrogen) and Superscript Reverse transcription (Invitrogen). Primers 
and conditions are listed in Table S1. ICER sense primer corresponds to the 
5 untranslated region of ICER and the anti-sense to bp 496–516 of CREM 
(Tetradis et al., 1998).
For quantitative (q) PCR, GAPDH and RALDH2 mRNA levels were 
determined with primers/probe (Roche; Table S1) using TaqMan Gene Ex-
pression assays (Applied Biosystems) with TaqMan Gene Expression Master 
Mix (Applied Biosystems), according to the manufacturer’s instructions. 
Changes in gene expression relative to the endogenous control GAPDH 
were calculated using the formula 2-CT. Fold changes in expression relative 
to control DCs were calculated according to the 2-CT method.
In vitro T cell proliferation assays. CD8+ T cells were enriched from 
splenocytes of F5 mice using a CD8+ negative isolation kit (Dynal; Invitro-
gen) and labeled with 1 µM CFSE for 10 min at 37°C. DCs were purified 
with anti-CD11c or MHC class II microbeads beads (Miltenyi Biotec) ac-
cording to the manufacturer’s instructions, and pulsed with 0.1 µg/ml 
NP366–374-peptide for 45 min at 37°C. 25 × 103 DCs were plated into 96-well 
flat-bottom plates with 75 × 103 CFSE-labeled CD8+ F5 T cells. After 4 d, 
cells were stained with anti-TCR and anti-CCR9 or -PSL antibodies with 
appropriate secondary antibodies and analyzed by flow cytometry.
In vivo homing experiments. F5 T cells activated in vitro by NP366–374  
peptide-pulsed control or SN-conditioned DCs were labeled with 0.1 µM CFSE 
or 20 µM CTO, pooled at a 1:1 ratio, and 2 × 106 total donor cells were 
transferred i.v. into B6.Ly5.1 mice that had been sensitized with oxazolone and 
challenged on the ear as previously described (Johnson et al., 2006). After 16 h, 
recipient mice were sacrificed, perfused, and single cell suspension made from 
the spleen, ear, and intestine as previously described (Weigmann et al., 2007). 
Cells were stained with anti–mouse CD45.2 for analysis by flow cytometry.
Adoptive transfer experiments. CD8+ T cells were enriched from spleno-
cytes of F5 mice, labeled with 1 µM CFSE, and 5 × 105 cells were trans-
ferred into C57BL/6 recipients by i.v. tail vein injections. 1 d later, mice were 
injected i.v. with 50 µg NP366–374–peptide with 10 µg LPS. After 60 h, spleens 
were harvested, digested with collagenase, and stained with ALD and CD11c, 
as previously described, or stained with anti-CD8 and anti–CCR9 antibodies 
for analysis by flow cytometry.
Western blots. Cell pellets were lysed in 1% Igepal, 0.5% sodium deoxy-
cholate, and 0.1% SDS with inhibitors (1 mM phenylmethylsulfonyl fluoride, 
50 mM sodium fluoride, 2 mM sodium orthovanadate, and complete prote-
ase inhibitor [Roche]). Lysate was separated on 15% polyacrylamide gel via 
SDS-PAGE, transferred to a PVDC membrane (Hybond; GE Healthcare), 
and blocked with PBS, 5% BSA, and 0.1% Tween-20. Anti–CREM-1 anti-
body (X-12; 1:500; Santa Cruz Biotechnology, Inc.) was added in blocking 
buffer overnight at 4°C and detected with horseradish peroxidase–conjugated 
secondary antibody before developing using Super Signal chemiluminescent 
reagent (Thermo Fisher Scientific).
Statistical analysis. Data were analyzed using a two-tailed Student’s t test.
Online supplemental material. Fig. S1 shows that both ALD-positive and   
-negative subsets stimulated robust peptide-specific T cell proliferation in vitro 
and that RALDH activity is common to differing DC subsets in vivo. Fig. S2 
shows that CD11c+ DCs have equivalent expression of MHC class II and 
CD86 to control DCs and that skin SN-conditioned DCs produced equivalent 
Reagents and media. Recombinant mouse G-CSF, M-CSF, TGF-, IL-4, 
IL-6, IL-7, IL-10, IL-12, and IL-13 and human FLT3-L and GM-CSF were 
purchased from PeproTech. Mouse TSLP and the PGE2 ELISA kit were ob-
tained from R&D Systems and CPG1826 from InvivoGen. Ciglitazone, all-
trans RA, Escherichia coli LPS, trypsin-coated agarose beads, SC19220, and 
AH23848 were obtained from Sigma-Aldrich. PGD, PGF, PGI, thromboxane, 
and AH6809 were obtained from Cayman Chemical and PGE2 was from the 
John Radcliffe Hospital Pharmacy (Oxford, London, UK). The EP-specific 
agonists  ONO-D1-004  (EP-1),  ONO-AE1-259  (EP-2),  ONO-AE-248 
(EP-3), and ONO-AE1-329 (EP-4) were a gift from the ONO Pharmaceu-
tical Company. Mouse GM-CSF and human IL-4 were produced in house. 
IL-12p40 ELISA was performed with capture (C15.6) and detection (C17.8) 
antibodies purchased from eBioscience.
Cell lines. Primary skin stromal lines were generated from adult C57BL/6 
mice by digesting full-thickness skin in 1 mg/ml of type II collagenase 
(Worthington Biochemical Corporation) and 10 µg/ml DNase (Sigma- 
Aldrich) and grown in complete DME (DME supplemented with 1 mM   
sodium pyruvate, 25 mM Hepes, MEM-NEA, 50 µM 2-mercaptoethanol,   
l-glutamine, and antibiotics) with 10% FCS (DME-10) until confluent adherent 
monolayers developed. 3T3 fibroblasts were maintained in DME-10 and the 
EL-4 thymoma in complete RPMI with 10% FCS (RP-10). To generate cell line 
SNs, cells were grown until 50–70% confluent and media was replaced with 
fresh RP-10. Cells were cultured for a further 2 d before 0.22 µM SN was 
harvested and filtered for use. In some instances, cells were grown for the final 
2 d in the presence of 1 µM fumonisin B1 (Sigma-Aldrich), 1 µM NBDJ 
(Sigma-Aldrich), or 1 µM indomethacin (Sigma-Aldrich), or SN was sub-
sequently heated (80°C for 20 min) and digested with 5–10 U/ml trypsin- 
agarose beads for 2 h at 37°C (Sigma-Aldrich). The following formulae was 
used to compare the relative inhibitory activity of treated versus untreated 
SN: [(without SNa – treated SNa)/(without SNa – untreated SNa)] × 100 = % 
relative inhibition by treated SN, where a = % ALD+ of CD11c+ cells.
Flow  cytometry. Antibodies  for  flow  cytometry  were  as  follows:  anti-
CD11c APC  (N418),  anti-TCR APC  (H57-597),  anti-CD3  eFluor  450 
(17A2), anti-CD45.2 APC (104), anti-CD103 biotin (M290), anti–CD11b-
APC (M1/70), anti-CD8 APC (53.67), anti-Ia/Ie FITC (M5/114), anti-
CD86 PE (GL-1), rat-IgG2a PE isotype control, and anti–human Fc PE 
(eBioscience). Anti-CCR9 PE (242503) and the P-selectin/human Fc chimeric 
protein were obtained from R&D Systems. Anti–human CD86 APC (2331) 
was obtained from BD. ALD staining (STEMCELL Technologies) was used 
as per the manufacturer’s instructions. 10 µg/ml propidium iodide (Sigma-
Aldrich) was added immediately before analysis on FACSCalibur or Cyan 
(BD) flow cytometers. Data were analyzed with FlowJo software (Tree Star).
Isolation of CD11c+ DCs from tissues. CD11c+ DCs were isolated from 
tissues essentially as previously described (Vremec and Shortman, 1997). In brief, 
organs were digested in 1 mg/ml of type II collagenase (Worthington Bio-
chemical Corporation) with 10 µg/ml DNase (Sigma-Aldrich) for 20 min at 
room temperature before the addition of 10 µM EDTA for a final 5 min. 
In some instances, DCs were subsequently enriched with anti-CD11c micro-
beads (Miltenyi Biotec) as per the manufacturer’s instructions.
Generation of mouse BM-DCs. BM was isolated from the femur and 
tibia of mice and cultured in 6-well plates (106 cells/well). For FLT3-L DCs, 
cells were cultured with 100 ng/ml of human recombinant FLT3-L in RP-10 
with GM-CSF, G-CSF, M-CSF, TSLP, TGF-, IL-4, IL-6, IL-7, IL-10, IL-12,   
IL-13, or PGE2 at 20 ng/ml, or RA and 100 µM Ciglitizone. After 3 d,   
0.25 ng/ml LPS was added and cells were harvested the next day. For GM-CSF–
cultured BM-DCs, cells were cultured with 20 ng/ml GM-CSF in RP10 
alone or with SN at 75% of culture volume (unless otherwise stated). After   
3 d, 0.25 ng/ml LPS was added and cells were harvested the next day. For in 
vitro proliferation assays, DCs were subsequently enriched with anti-CD11c 
or anti–MHC class II microbeads (Miltenyi Biotec). Human mo-DCs were gen-
erated essentially as previously described (Sallusto and Lanzavecchia, 1994). 
In brief, CD14+ monocytes were purified from buffy coats with CD14+ 772 PGE2 inhibition of retinoic acid–producing DCs | Stock et al.
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or enhanced levels of IL-12 upon TLR stimulation. Fig. S3 shows that exogenous 
PGE2 alone, in the absence of skin SN, has reduced suppressive activity.   
Fig. S4 shows that EP-4 deficiency did not change the frequency or phenotype 
of DCs during BM-DC development and appeared to enhance DC RALDH 
expression selectively. In vivo, EP-4 KO mice showed a statistically significant 
increase in the frequency of RALDH+ DCs in the pLNs, but not in mLNs 
or the spleen. Fig. S5 shows that, when added during mo-DC differentiation, the 
cAMP analogue dibutyryl-cAMP suppressed the development of RALDH+ 
DCs in vivo. Fig. S6 shows that PGE2 is present constitutively in the small 
intestine at levels similar to those found in the skin and the spleen. Table S1 
lists the primers and conditions used in PCR. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20101967/DC1.
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